Soo-Kyung Lee

Is missing (Short communication)

PrabotulinumtoxinA has been identified as an effective agent against crow’s feet. Our study, which included Korean patients with moderate to severe crow’s feet, was undertaken to compare the efficacy and safety of PrabotulinumtoxinA and placebo treatments. Of the 90 study participants, 60 received prabotulinumtoxinA (24 U), whereas 30 received a placebo. The primary outcome assessment included facial wrinkle grading by investigators. At week 4, 69.64% of patients in the prabotulinumtoxinA group exhibited minimal crow’s feet severity; in contrast, a 0% improvement was observed in the placebo group (p < 0.0001). At week 12, the improvement rates were 30.36% for prabotulinumtoxinA and 6.90% for the placebo, demonstrating a significant difference (p = 0.0152). Based on the independent review panel’s assessment at week 4, the improvement rate was 39.29% in the prabotulinumtoxinA group and 3.45% in the placebo group during maximum smiling. Additionally, patient satisfaction was notably higher in the prabotulinumtoxinA group (32.14%) than in the placebo group (10.34%) at week 4 (p = 0.0289). Both treatments displayed comparable safety profiles, with only mild local reactions reported as ADRs for one patient from the prabotulinumtoxinA group. Thus, prabotulinumtoxinA demonstrates significant potential as a potent and safe remedy for crow’s feet.

Is missing (Short communication)

Kim JH, et al. Ann Dermatol. 2023 May;35:e61. https://doi.org/10.5021/ad.21.029

Kim JH, et al. Ann Dermatol. 2023 Feb;35(1):66-70. https://doi.org/10.5021/ad.21.023

Kim JH, et al. Clin Exp Vaccine Res. 2022 Sep;11(3):298-301. https://doi.org/10.7774/cevr.2022.11.3.298

Lee JH, et al. Ann Dermatol. 2022 Oct;34(5):378-381. https://doi.org/10.5021/ad.20.145

Current therapeutic agents for onychomycosis have limited efficacy or cause side effects. Recently, successful treatment using fractional CO2 lasers has been reported; however, the results are inconsistent. We analyzed the real-world effectiveness of a Fractional CO2 laser for the treatment of Onychomycosis A single-center retrospective chart review was conducted during January 2015-December 2018. Patients, diagnosed with onychomycosis through fungal culture and/or potassium hydroxide staining, underwent three or more fractional CO2 laser treatments and used topical antifungal agents. Treatment effects were assessed by using clinical images at 6, 12 months, and the last visit. Ninety-six patients were included; they underwent an average of 7.7 laser treatment sessions. Finally, 15 patients (15.6%) showed complete response (100% clearing of all nails), 24 patients (25%) showed partial response, and 57 patients (59.4%) showed no response (no 100% clearing of nails among all treated toenails per patient including mild improvement or temporary cosmetic improvement). Multivariable logistic regression analysis revealed longer disease duration (p = 0.006, OR = 1.16 [95% CI: 1.05-1.31]), patients with diabetes (p = 0.021, OR = 9.82 [95% CI: 1.75-94.01]) and fewer number of laser treatment sessions (p = 0.001, OR = 0.76 [95% CI: 0.64-0.89]) were significantly associated with non-response group. In conclusion, fractional CO2 laser with topical antifungal could be a safe alternative treatment in patients with onychomycosis, who are difficult to take oral antifungals.

Background: In order to successfully treat scabies and to prevent its spread, it is important to identify the factors that can influence the outcome of scabies treatment.Objectives: This study was designed to evaluate the risk factors associated with treatment resistance scabies during use of an effective topical medication.Methods: A retrospective cohort study was performed in patients with scabies infestations confirmed by potassium hydroxide (KOH) examinations. Patient characteristics, clinical features and treatment history were collected. The treatment resistance group included patients with persistent scabies infestations for more than 28 days after initiation of antiscabies treatment with 5% permethrin cream.Results: In total, 138 patients with scabies infestations treated between January 2017 and December 2020 were included in this study. Of these, 100 (72.5%) patients were treated successfully, while 38 (27.5%) patients experienced treatment resistance. In the univariable analysis, risk factors for treatment resistance scabies included impaired cognitive function (OR = 2.66, 95% CI, 1.15–6.14), limited mobility (OR = 2.97, 95% CI, 1.30–6.83), inpatient status (vs. outpatient, OR = 3.3, 95% CI, 1.28–8.54), topical steroid use before diagnosis (OR = 3.52, 95% CI, 1.61–7.81), systemic steroid use before diagnosis (OR = 3.57, 95% CI, 1.26–10.34) and a positive KOH exam after the first treatment (OR = 7.25, 95% CI, 3.24–17.11). In the multivariable analysis, limited mobility (OR = 3.46, 95% CI, 1.02–12.11) and topical steroid use before diagnosis (OR = 3.65, 95% CI, 1.41–9.75) were significant predictive factors for treatment resistance scabies.Conclusions: Scabies patients with limited mobility and topical steroid use before diagnosis are at high risk of treatment resistance. Dermatologists should take these findings into consideration when treating patients with scabies infestations.